1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Diurnal Ltd - Product Pipeline Review - 2014

Diurnal Ltd - Product Pipeline Review - 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 27 pages

Diurnal Ltd - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Diurnal Ltd - Product Pipeline Review - 2014’, provides an overview of the Diurnal Ltd’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Diurnal Ltd’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Diurnal Ltd including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Diurnal Ltd’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Diurnal Ltd’s pipeline products

Reasons to buy

- Evaluate Diurnal Ltd’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Diurnal Ltd in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Diurnal Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Diurnal Ltd and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Diurnal Ltd
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Diurnal Ltd and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Diurnal Ltd - Product Pipeline Review - 2014
Table of Contents

Diurnal Ltd Snapshot 5
Diurnal Ltd Overview 5
Key Information 5
Key Facts 5
Diurnal Ltd - Research and Development Overview 6
Key Therapeutic Areas 6
Diurnal Ltd - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Diurnal Ltd - Pipeline Products Glance 11
Diurnal Ltd - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Diurnal Ltd - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Diurnal Ltd - Drug Profiles 14
hydrocortisone MR 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
hydrocortisone IR 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
(triiodothyronine + thyroxine) 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Rheumacort 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
testosterone 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Diurnal Ltd - Pipeline Analysis 20
Diurnal Ltd - Pipeline Products by Target 20
Diurnal Ltd - Pipeline Products by Route of Administration 21
Diurnal Ltd - Pipeline Products by Molecule Type 22
Diurnal Ltd - Pipeline Products by Mechanism of Action 23
Diurnal Ltd - Recent Pipeline Updates 24
Diurnal Ltd - Locations And Subsidiaries 25
Head Office 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Tables

Diurnal Ltd, Key Information 5
Diurnal Ltd, Key Facts 5
Diurnal Ltd - Pipeline by Indication, 2014 7
Diurnal Ltd - Pipeline by Stage of Development, 2014 8
Diurnal Ltd - Monotherapy Products in Pipeline, 2014 9
Diurnal Ltd - Combination Treatment Modalities in Pipeline, 2014 10
Diurnal Ltd - Phase II, 2014 11
Diurnal Ltd - Phase I, 2014 12
Diurnal Ltd - Preclinical, 2014 13
Diurnal Ltd - Pipeline by Target, 2014 20
Diurnal Ltd - Pipeline by Route of Administration, 2014 21
Diurnal Ltd - Pipeline by Molecule Type, 2014 22
Diurnal Ltd - Pipeline Products by Mechanism of Action, 2014 23
Diurnal Ltd - Recent Pipeline Updates, 2014 24

List of Figures

Diurnal Ltd - Pipeline by Top 10 Indication, 2014 7
Diurnal Ltd - Pipeline by Stage of Development, 2014 8
Diurnal Ltd - Monotherapy Products in Pipeline, 2014 9
Diurnal Ltd - Pipeline by Top 10 Target, 2014 20
Diurnal Ltd - Pipeline by Top 10 Route of Administration, 2014 21
Diurnal Ltd - Pipeline by Top 10 Molecule Type, 2014 22
Diurnal Ltd - Pipeline Products by Top 10 Mechanism of Action, 2014 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ...

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Growth Hormone Secretagogue Recepto ...

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H2 2016

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.